Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialLaurent Servais, Frederick J. Schnell, Eugenio Mercuri et al.|Nucleic Acid Therapeutics|2021Cited by 128
DMD - TREATMENTSusan T. Iannaccone, Eugenio Mercuri, E. Koenig et al.|Neuromuscular Disorders|2021Cited by 2